Search

everythinglearnresearchcommunity

for

Search:↓

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Erlotinib can cause persistent excessive hair growth.

Gefitinib can cause rare scarring hair loss.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Low-dose sorafenib can cause severe facial acne, treatable with topical medication.

Ruxolitinib treatment may cause eyelash growth.

Ruxolitinib cream may help treat severe hair loss in children.

An HIV patient's complete hair loss was reversed after switching from lopinavir/ritonavir to nelfinavir.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Ritlecitinib is safe and may effectively treat alopecia areata.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Gefitinib can cause hair loss without scarring.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

The combination of encorafenib and binimetinib caused few skin issues.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Ritlecitinib is a new treatment for severe hair loss in people 12 and older.

A man developed alopecia areata after starting cancer treatment with vandetanib.